 Athira Pharma Inc NASDAQ: ATHA shares are falling Wednesday after the company announced topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton in patients with mild-to-moderate Alzheimers disease. Athira said the primary endpoint of change in biomarker. 